Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, that the Board of Directors of the Company at their Board Meeting held on Friday, February 06, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sunil Healthcare Ltd's Board of Directors, at their 266th meeting held on February 6, 2026 (4:17 PM to 5:55 PM), approved the Un-Audited Financial Results (both standalone and consolidated) for the third quarter and nine months ended December 31, 2025 of FY 2025-26. The auditor Singhi & Co, Chartered Accountants issued an unmodified (clean) Limited Review Report on both the standalone and consolidated results, confirming no material misstatements. The consolidated results include two foreign subsidiaries — Sunil Healthcare Mexico Sa De CV and Sunil Healthcare North America LLC. Standalone Q3 FY26 revenue from operations stood at Rs. 2,351.76 lakhs versus Rs. 2,046.43 lakhs in Q3 FY25, while standalone nine-month revenue rose to Rs. 6,799.69 lakhs from Rs. 6,221.75 lakhs in the comparable prior-year period.
Routine quarterly results disclosure with a clean auditor opinion, providing comfort on the reliability of the numbers. Standalone revenue shows YoY growth in both Q3 and 9M, which is mildly positive, but investors should examine the detailed statement for profit trends, margins, and subsidiary-level performance before drawing firm conclusions.